Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 22:10:1217-23.
doi: 10.2147/DDDT.S102458. eCollection 2016.

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study

Affiliations

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study

Kazuki Ide et al. Drug Des Devel Ther. .

Abstract

Purpose: The aims of this study were to investigate regional differences in hepatitis C virus (HCV) infection treatment with peginterferon and ribavirin in Japan and to develop and validate statistical models for analysis of regional differences, using generalized linear mixed models.

Methods: Individuals with chronic HCV infection were identified from the Japanese Interferon Database (registered from December 2009 to April 2013). The total sustained virologic response rate and the rate in each prefecture were calculated. In the analysis using generalized linear mixed models, the following four models were constructed: 1) prefecture as a fixed effect, 2) prefecture and other confounding variables as fixed effects, 3) prefecture as a random effect, and 4) prefecture as a random effect and other confounding variables as fixed effects. The quality of the model fit was assessed using the Akaike information criterion and the Bayesian information criterion. All statistical analyses were performed using SAS Version 9.4 for Windows.

Results: From 36 prefectures, 16,349 cases were recorded in the study period. Of these, 4,677 were excluded according to certain criteria. The total sustained virologic response rate was 59.9% (range, 43.9%-71.6%). The statistical model including prefecture as a random effect and other confounding variables as fixed effects showed the best fit based on the Akaike information criterion (13,830.92) and Bayesian information criterion (13,845.17).

Conclusion: Regional differences may exist in HCV infection treatment in Japan. The model including prefecture as a random effect and other confounding variables as fixed effects was appropriate for analysis of such regional differences. Additional studies considering the medical situations of each patient would provide useful information that could contribute to improve and standardize HCV infection treatment.

Keywords: generalized linear mixed model; hepatitis C virus; interferon; nationwide database; regional differences.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of sustained virologic response (SVR) rate in Japan.
Figure 2
Figure 2
Parameters of sustained virologic response (SVR) dispersion and quality of model fit. Notes: (A) Model including prefecture as a fixed effect. (B) Model including prefecture and other confounding variables as fixed effects. (C) Model including prefecture as a random effect. (D) Model including prefecture as a random effect and other confounding variables as fixed effects. β is the fixed-effect parameter, and u is the random-effect parameter. Abbreviations: AIC, akaike information criterion; BIC, bayesian information critreion.

Similar articles

References

    1. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374. - PMC - PubMed
    1. World Health Organization [webpage on the Internet] Hepatitis C Fact Sheet No. 164 July 2015. 2015. [Accessed August 12, 2015]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
    1. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55(suppl 1):S10–S15. - PubMed
    1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–1444. - PMC - PubMed
    1. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44. - PubMed

Publication types